Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 149 Matches

Emtricitabine_V18R1_Simcyp_20200212

Model Files Publication

https://www.ncbi.nlm.nih.gov/pubmed/31602556 FO, mainly renally excreted. Has been used for HV, Pregnancy population and elderly population.

Search Score: 1

Famotidine_V15R1_USFDA_20170810

Model Files Publication

http://onlinelibrary.wiley.com/doi/10.1002/cpt.750/full Famotidine compound file in healthy volunteers. Evaluation of the effect of renal impairment on the PK of OAT substrates. NOTE: MW is slightly different between model file and Table 1.

Search Score: 1

Iloperidone_V12R2_USFDA_20160510

Model Files Publication

Note/correction: predicted B/P should be 0.70, predicted Fa should be 0.84

Search Score: 1

Lumefantrine

Model Files Publication

Brand Name(s) include: Coartem (artemether, lumefantrine), Riamet (artemether, lumefantrine)

Disease: Malaria

Drug Class: Antimalarials

Related Files: Artemether – drug partner in fixed dose combinations

Date Updated: December 2022

The model at-a-glance

Absorption Model	First-Order
Volume of Distribution Details	Full PBPK (Method 2) Note: Kp scalar and Kp adipose used
Route of Elimination	CYP3A4 (40%); non-specific hepatic metabolism (60%)
Perpetrator DDI	CYP2D6 Inhibitor
Validation	Two clinical studies describing single dose exposure and two describing multiple dose exposure of lumefantrine were used to verify the PBPK model. The single dose exposures were within 2-fold of observed for both studies. The multiple dose exposures were within 1.25-fold of observed for both studies. Clinical DDI studies with rifampicin and efavirenz in healthy volunteers where lumefantrine was the victim of CYP3A4-mediated DDIs were over-predicted (>2-fold) using the PBPK model. An alternative clinical efavirenz DDI study in HIV patients and a clinical DDI with ritonavir in healthy volunteers were well predicted (within 1.25-fold of observed). As the effect of CYP3A4 inhibition was independently verified and there appeared to be variability in the extent of induction on lumefantrine PK, the fmCYP3A4 of 40% was considered verified.
Limitations	Plasma concentrations of lumefantrine following a single dose are less accurately predicted than those following multiple dose administration. As the Day 7 plasma concentrations following repeat administration of lumefantrine, are more critical (linked to cure rates) than after the first dose, this was deemed acceptable. The model can be used to prospectively predict CYP2D6-mediated DDIs but in the absence of verification of CYP2D6 inhibition, this should be accompanied by appropriate sensitivity analysis.
Updates in V19	Updates in vitro data based on new information B:P ratio 0.6 -> 0.55 CYP2D6 Ki (µM) 2.2 -> 1.8

Search Score: 1

Search the PBPK Model Repository

Searching Tips

Emtricitabine_V18R1_Simcyp_20200212

Famotidine_V15R1_USFDA_20170810

Iloperidone_V12R2_USFDA_20160510

Lumefantrine

The model at-a-glance

Your Privacy